Sir John Irving Bell, B.E., MA, DM, FRCP is a Senior Advisor at GHO Capital Partners LLP. Sir Bell is a UK Government Healthcare Advisor. He co-founded Wellcome Trust Centre for Human Genetics at the University of Oxford. He serves as a Director of Oxagen Limited. He has been a Non Executive Director of Roche Holding AG since 2001. He has been a Director of Immunocore Limited since March 30, 2015. He serves as a Non-Executive Director at Genentech, Inc. and Isis Innovation Limited. Sir Bell serves as a Main Board Member of Roche AG. He serves as a Trustee of The Rhodes Trust. He serves as a Member of Life Sciences Advisory Board at Advent Venture Partners. He serves as a Member of Scientific Advisory Board of Protemix Corporation Limited and AstraZeneca. He serves as a Member of Partnership Board at Oxford comprehensive Biomedical Research Centre. He served as a Non-Executive Director of Chiron Pharmaceuticals Limited since September 1993. He served as a Non-Executive Director of Powderject Pharmaceuticals PLC since September 1993. He is a Member of Council of the University of Oxford and a Member of Council for the Medical Research Council. He has been the President of the Academy of Medical Sciences and Regius Professor of Medicine at Oxford University since 2002, where he directs the largest biomedical research department in the UK. He has particular scientific interests in the genetics of immunologically mediated diseases, specifically rheumatoid arthritis, type 1 diabetes, inflammatory bowel disease and autoimmune thyroid disease. At Stanford, he developed research interests in the area of immunology and genetics with a particular focus on characterizing the molecular events associated with susceptibility to autoimmune diseases. He returned to Oxford as a Wellcome Trust Senior Clinical Fellow in 1987 and was elected to the Nuffield Professorship of Clinical Medicine in Oxford in 1992. In 2008, he was made a Fellow of the Royal Society and was made a Knight Bachelor for his services to Medical Science. He was appointed by the Chancellor of the Exchequer in 2006 to Chair the Office for the Strategic Coordination of Health Research (OSCHR), the body responsible to co-ordinate the research functions of the NIHR and the MRC. He went to Oxford as a Rhodes Scholar to train in medicine and undertook Postgraduate training in London and at Stanford University. He studied FRCP from The Royal College of Physicians in 1992 and B Med Sci Honours in Medical Science from University Of Alberta in 1975. He studied BM BCh from Magdalen College in 1979, BA in Physiological Sciences in 1976 and DM in 1990 from Magdalen College.

 Physiological Sciences